跳至主要内容
临床试验/NCT04961450
NCT04961450Enrolling By Invitation不适用

A Study on the Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China

Peking University Third Hospital1 个研究点 分布在 1 个国家目标入组 2,500 人开始时间: 2021年6月24日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
2,500
试验地点
1
主要终点
Biomarker differences of the spectrum disease

研究概览

简要总结

  1. To investigate the biomarkers of MND/FTD spectrum disease
  2. To explore the possible pathogenesis of MND/FTD

详细描述

Motor neuron disease (MND) is a group of disease characterized by motor neuron disorders and neurodegeneration. MND and frontotemporal dementia (FTD) were believed to comprise a neurodegenerative disease spectrum. The prognosis of the disease spectrum varies according to the type of disease, and the diagnosis of patients is often delayed due to insufficient diagnostic biomarkers. In recent years, the academic community has made significant progress in the study of biomarkers of the disease, but there is still a lack of specific biomarkers with strong diagnostic value. Besides, the low prevalence makes it difficult to carry out studies with large samples. The aim of this study was to explore diagnostic biomarkers of the disease spectrum by collecting variable samples from a large group of patients. The findings will both offer a better understanding of MND/FTD spectrum disease and also support the development of a model to study other rare diseases.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December
  • Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines
  • Informed consent signed Exclusion Criteria
  • Patients who receive alternative diagnoses during the follow-up.
  • Patients who refuse to sign informed consent.
  • Control group:
  • Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.
  • Exclusion criteria:
  • Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.
  • Individuals who refuse to sign informed consent.

排除标准

  • 未提供

结局指标

主要结局

Biomarker differences of the spectrum disease

时间窗: through study completion, less than 10 years.

Biomarkers including specific protein, miRNA, DNA , which was obtained by collecting blood, saliva, feces, cerebrospinal fluid, muscle tissue and nerve tissue. The differences of biomarkers between patients and healthy subjects were analyzed statistically in general.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验